Molluscum contagiosum

Novan to Report Second Quarter 2022 Financial Results on August 11, 2022

Retrieved on: 
Thursday, August 4, 2022
Novin, Psoriasis, Pharmacy, Skin, GLOBE, SB206, Molluscum contagiosum, Marketing, Patient, Acquisition, Acne, Rosacea, Investor, Conference, Pharmaceutical industry

DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday, August 11th.

Key Points: 
  • DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday, August 11th.
  • Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m.
  • The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team.
  • Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases.

VERRICA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Verrica Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, August 4, 2022
Legal, Professional Services, Jeanne Eagels, Lists of schools in England, Food, Defendant, District court, NDA, Endpoint security, Molluscum contagiosum, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, New Drug Application, P.C, Court, CMO, Person, LLC, Telephone, NASDAQ, Animal, Risk management

Investors have until August 5, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until August 5, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • In December 2020, Verrica submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking regulatory approval of VP-102 for the treatment of molluscum.
  • In November 2021, Verrica resubmitted the NDA for VP-102, claiming [t]he resubmission addresses the successful resolution of inspection deficiencies at the manufacturing facility.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

VRCA FRIDAY DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action – VRCA

Retrieved on: 
Thursday, August 4, 2022
Titan, Lists of schools in England, I-Space (Chinese company), Food, THE, Facebook, Advertising, Class, LinkedIn, Molluscum contagiosum, Cantharidin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TO, WHY, GLOBE, New Drug Application, Court, Twitter, NASDAQ, Insurance, Tobacco

WHAT TO DO NEXT: To join the Verrica class action, go to https://rosenlegal.com/submit-form/?case_id=6828 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Verrica class action, go to https://rosenlegal.com/submit-form/?case_id=6828 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

DEADLINE ALERT for APYX, VRCA, APPS, TDOC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Wednesday, August 3, 2022
EBITDA, People's Law Office, Law, Teladoc Health, Defendant, Suite, Company, NDA, Class, Molluscum contagiosum, Investment, Time, GLOBE, Telephone, Growth, Security (finance), Risk management, Public relations

BENSALEM, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

Common Warts Drug Pipeline Report 2022 Featuring Verrica Pharmaceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Pharma, & NIELSEN BioSciences - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 3, 2022
Health, Pharmaceutical, Wart, Molluscum contagiosum, WHIM syndrome, Route of administration, Patient, WHIM, CXCR4, GMP, Cantharidin, Administration, Therapy, Route, Pharmaceutical industry, Vaccine

The "Common Warts - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Common Warts - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This ''Common Warts - Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Common Warts pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence R&D Common Warts.
  • The companies which have their Common Warts drug candidates in the most advanced stage, i.e phase III include X4 Pharmaceuticals
    Common Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals, Inc. -VRCA

Retrieved on: 
Monday, August 1, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LLP, Company, GLOBE, Food, VP, CMO, NDA, New Drug Application, NASDAQ, Endpoint security, News, Molluscum contagiosum, LLC, Pomerantz, Pharmaceutical industry

NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals, Inc. (Verrica or the Company) (NASDAQ:VRCA).

Key Points: 
  • NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals, Inc. (Verrica or the Company) (NASDAQ:VRCA).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Verrica and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

DEADLINE ALERT for APYX, VRCA, APPS, and TDOC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, August 1, 2022
Time, Investment, GLOBE, Twitter, Law, NDA, Molluscum contagiosum, Company, Defendant, Lists of schools in England, Complaint, Teladoc Health, Suite, Growth, EBITDA, Mail, Risk management, Pharmaceutical industry

LOS ANGELES, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan

Retrieved on: 
Monday, August 1, 2022
License, GLOBE, End-user license agreement, Cantharidin, Skin, U.S. Securities and Exchange Commission, Dermatology, Molluscum contagiosum, Partnership, Private Securities Litigation Reform Act, Social stigma, Sibling, Achievement, Inflammation, Wart, Disease, FDA, Company, Fomite, Pain, Therapy, Genetically modified bacteria, Prevalence, Itch, Pharmaceutical industry, Torii

WEST CHESTER, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Torii Pharmaceutical Co., Ltd. (“Torii”) dosed the first patient in its Phase 3 trial of VP-102 (referred to as TO-208 in Japan) for molluscum contagiosum in Japan, triggering an $8 million milestone payment from Torii to Verrica.

Key Points: 
  • We are pleased to see Torii dose the first patient in its Phase 3 trial of VP-102 for the treatment of molluscum contagiosum in Japan, said Ted White, Verricas President and Chief Executive Officer.
  • In March 2021 Torii exercised its option to acquire the exclusive license to develop and commercialize Verricas product candidates for the treatment of molluscum contagiosum and common warts in Japan.
  • Torii is responsible for all development activities and costs in support of obtaining regulatory approval in Japan.
  • In addition, Verrica has successfully completed a Phase 2 study ofVP-102for the treatment of common warts and a Phase 2 study ofVP-102for the treatment of external genital warts.

Verrica Pharmaceuticals Inc. Investors: Class action lawsuit filed on behalf of investors; Deadline August 5, 2022; the Portnoy Law Firm

Retrieved on: 
Monday, August 1, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Cantharidin, Dermatology, Food, VP, Molluscum contagiosum, CMO, NDA, New Drug Application, Skin, NASDAQ, Endpoint security, News, Review, Company, Lists of schools in England, Therapy, LLC, Pharmaceutical industry

LOS ANGELES, July 31, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) investors that a class action filed on behalf of investors. Verrica investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, July 31, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) investors that a class action filed on behalf of investors.
  • Verrica investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • Verricas lead product candidate, VP-102, is a drug device combination of Verricas topical solution, cantharidin, administered through a single-use precision applicator.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Teladoc, Verrica, Apyx, and Waste Management and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, August 1, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Negotiation, New Drug Application, News, Company, Lists of schools in England, Waste Management (corporation), Teladoc Health, LLC, SMR, EBITDA, Acquisition, Tripura Merger Agreement, Walmart, Prospectus, Molluscum contagiosum, Defendant, DOJ, Growth, Office of Inspector General, U.S. Department of Health and Human Services, Waste management, GLOBE, Industry, Food, Disclosure, CMO, Failure, U.S. Department of Justice Office of Legislative Affairs, Endpoint security, D2C, Mergers and acquisitions, FDA, Amazon (company), Tax, GFL Environmental, BetterHelp, Advanced Energy, Energy Products Inc, NYSE, NDA, NASDAQ, Mental health, P.C, Coagulation, TDOC, Depreciation, Risk management, Pharmaceutical industry, Audit, Animal, Bank, Note

Throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.

Key Points: 
  • Throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • In the Notes prospectus, Waste Management represented that the Merger would close by the first quarter of 2020.
  • For more information on the Waste Management class action go to: https://bespc.com/cases/WM
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.